Asset profile
Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor (MCR) system. Its product candidates are targeted, receptor-specific therapeutics for the tre…
Newest first.
Palatin Presents Preclinical Data on MC4R Agonist PL2001 at ObesityWeek 2026
Other drugs and candidates from the same company tracked in this sector.